An interventional study of Fresh Autologous whole Blood and Standard of Care Expectant management of bleeding in Cardiac Disease and Bleeding Postoperative, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 646 studies in Heart Diseases with a site in United States — 92 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.
Among the 646 studies in Heart Diseases with a site in United States, this one is the 285th largest by planned enrollment of the 430 interventional ones that give a count, is one of 14 that started in 2022, is one of 244 with no phase, reaches primary completion later than 16 of the 128 other live ones, and was the 414th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →92 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Abiomed Inc. · Sites in United States
Ages 18–80
Edwards Lifesciences · Sites in United States
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
646 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 62 · Phase 3 71 · Phase 4 36
First in 1973; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 161 across the 430 interventional studies, 300 across the 206 observational. Of the 469 that completed or were terminated, 158 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 646 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 5 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
40 of the studies in Heart Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
| NCT06891222Mayo ClinicA Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening | 2026-11 |
| NCT06703489Medtronic Cardiac Ablation SolutionsSafety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS) | 2026-11 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 646 studies in Heart Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Autologous blood transfused at the end of cardiopulmonary bypass will reduce total blood loss 24 hours after surgery and improve mitochondrial oxygen delivery measured by plasma succinate levels.
The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.
Cardiac surgery carries a significant risk of bleeding requiring transfusion of stored blood products and blood transfusion associated with cardiac surgery consumes 20% of the blood supply worldwide. Although transfusion may be life-saving, significant risks of complications such as lung injury or even an increase in mortality are associated with transfusion. Decreasing transfusion requirements during cardiac surgery has the potential to reduce the rate of complications, improve patient outcomes, and reduce cost resulting in increased value for both the patient and the health system as a whole. Collection of autologous blood before cardiopulmonary bypass (CPB) for transfusion after CPB has been shown to be both safe and effective for reducing blood loss during cardiac surgery, but this intervention has not been targeted to a patient population at high risk for bleeding and transfusion. Fresh whole blood has the capacity to restore coagulation system function during profound coagulopathy in a trauma setting or following massive transfusion by an unknown mechanism. One unit of fresh whole blood is able to restore clotting function equivalent to that achieved by 10 units of pooled platelets. Autologous whole blood collection prior to CPB for transfusion post-operatively has been shown to improve coagulation and decrease clot lysis but is not routinely performed because 90% to 95% of patients do not have extensive blood loss and subsequent coagulopathy. Coupling accurate pre-operative bleeding risk prediction with autologous fresh whole blood collection for transfusion after CPB would target an established, low cost, low risk intervention to an at risk patient population who may experience significant benefit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
Other: Fresh Autologous whole Blood
the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
Other: Standard of Care Expectant management of bleeding
Subjects randomized this arm will receive fresh autologous whole blood
the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
Estimated Blood Loss
Blood loss is estimated as a percent of total estimated blood volume in the first 24 hours after cardiac surgery.
Time frame: Within 24 hours after surgery
Number of allogenic transfusions given
Allogenic blood product transfusion requirements
Time frame: 31 days
Severity of peri-operative stroke
The severity of peri-operative stroke will be measured by the National institute of health stroke scale
Time frame: 31 days
Incident of peri-operative stroke
The incident of peri-operative stroke will be measured by the National institute of health stroke scale
Time frame: 31 days
Development of Post-operative delirium
Measured by Confusion Assessment Method - Intensive Care Unit
Time frame: 31 days
Development of Myocardial Infarction
As measured by physiological parameters
Time frame: 31 days
Development of Heart failure
As measured by physiological parameters
Time frame: 31 days
Detection of New Onset Atrial fibrillation
As measured by an electrocardiogram
Time frame: 31 days
Development of Lung injury
Measured by a Pa02/Fi02 ratio
Time frame: 31 days
Time to extubation
Time from when the breathing tube was placed to the time when the breathing tube is removed
Time frame: 31 days
Development of Acute Kidney Injury
As measured by abnormal lab values
Time frame: 31 days
Initiation of renal replacement therapy
Time to start of renal replacement therapy
Time frame: 31 days
ICU length of stay
This will be measured by the number of days in ICU
Time frame: 31 days
Evaluation of Vasopressor requirements (1)
Measurement of the amount of vasopressors given
Time frame: 31 days
Evaluation of Vasopressor requirements (2)
Measurement of the types of vasopressors given
Time frame: 31 days
Change in endothelial function measured by flow mediated dilation of the brachial artery
Measurement of brachial artery dilation in response to flow by ultrasonography
Time frame: 24 hours after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2022 (actual). Primary completion is estimated for Aug 2025, 43 months after the start.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 43 months is above that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →